the Board meeting. The Subcommittee meeting will now start at 06:30 p.m. on February 26, 2014, and end at 08:00 p.m., and the Board meeting will now start at 8:30 a.m. on February 27, 2014. The meeting is partially closed to the public.

Dated: February 11, 2014.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2014–03407 Filed 2–14–14; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; Training and Career Development Application Review.

Date: April 16, 2014.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W110, Rockville, MD 20850 (Telephone Conference Call).

Contact Person: Robert Bird, Ph.D., Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W110, Bethesda, MD 20892– 8328, 240–276–6344 *birdr@mail.nih.gov.*

Name of Committee: National Cancer Institute Special Emphasis Panel; NCORP Minority Community Sites Review.

Date: April 22–23, 2014.

Time: 5:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Marriott Courtyard Gaithersburg, Washingtonian Center, 204 Boardwalk Place, Gaithersburg, MD 20878.

Contact Person: Michael B. Small, Ph.D., Chief, Program and Review Extramural Staff Training Office, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W412, Bethesda, MD 20892–9750, 240–276–6438 smallm@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; NCORP Research Base.

Date: April 29–30, 2014.

Time: 3:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 2W910/912, Rockville, MD 20850.

Contact Person: Shamala K. Srinivas, Ph.D., Scientific Review Officer, Office of Referral, Review, and Program Coordination, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W530, Bethesda, MD 20892– 9750, 240–276–6442, *shamala@mail.nih.gov.*

Information is also available on the Institute's Center's home page: http:// deainfo.nci.nih.gov/advisory/sep/sep.htm, where a roster and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS).

Dated: February 12, 2014.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2014–03397 Filed 2–14–14; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, March 20, 2014, 07:00 p.m. to March 21, 2014, 04:00 p.m., Courtyard Marriott Washingtonian Center, 204 Boardwalk Place, Gaithersburg, MD 20878 which was published in the **Federal Register** on February 07, 2014, 79FR7466.

The meeting notice is amended to change the location and time to 9609 Medical Center Drive, Room 5E30, Rockville, MD 20850, March 20, 2014, 10:00 a.m. to March 21, 2014, 3:30 p.m. Additionally the meeting is being held as a teleconference. The meeting is closed to the public. Dated: February 12, 2014. **Melanie J. Gray,** *Program Analyst, Office of Federal Advisory Committee Policy.* [FR Doc. 2014–03399 Filed 2–14–14; 8:45 am] **BILLING CODE 4140–01–P**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Pre-Clinical Evaluation and Commercial Development of Human Therapeutics for Liver Cancer and Ovarian Cancer Within the Scope of the Licensed Patent Rights

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to practice the inventions covered under the scope of the following patents and patent applications:

• United States Patent No. 8,207,142 issued Jun 26, 2012 entitled "Inhibitor of DNA Methylation" (HHS Ref. No. E– 081–2001/2–US–06);

• EP Patent No. 1418949 issued June 19, 2013, entitled "Inhibitor of DNA Methylation" (HHS Ref. No. E–081– 2001/2–EP–02) and validated in Great Britain, Germany and France;

• Australia Patent No. 2002322805 issued February 21, 2008 entitled "Inhibitor of DNA Methylation" (HHS Ref. No. E-081-2001/2-AU-03);

• Australia Patent No. 2008200601 issued November 25, 2010 entitled "Inhibitor of DNA Methylation" (HHS Ref. No. E-081-2001/2-AU-07);

• Canada Patent No. 2,454,147 issued May 21, 2013 entitled "Inhibitor of DNA Methylation" (HHS Ref. No. E–081– 2001/2–CA–04);

• Japan Patent Application No. 2003– 517229 filed July 30, 2002 entitled "Inhibitor of DNA Methylation" (HHS Ref. No. E-081-2001/2-JP-05); and

• Japan Patent No. 5416660 issued November 22, 2013 entitled "Inhibitor of DNA Methylation" (HHS Ref. No. E– 081–2001/2–JP–08)

to Metheor Therapeutics, Corporation ("METHEOR") a U.S. based company located in Shoreline, WA, USA. The patent rights in this invention have been assigned to the government of the United States of America.

The prospective exclusive evaluation option license territory may be